Financial reports
10-Q
2019 Q2
Quarterly report
13 Aug 19
10-Q
2019 Q1
Quarterly report
13 May 19
10-K
2018 FY
Annual report
22 Mar 19
10-Q
2018 Q3
Quarterly report
6 Nov 18
10-Q
2018 Q2
Quarterly report
13 Aug 18
10-Q
2018 Q1
Quarterly report
11 May 18
10-K
2017 FY
Annual report
28 Feb 18
10-Q
2017 Q3
Quarterly report
13 Nov 17
10-K/A
2016 FY
Annual report (amended)
30 Oct 17
10-Q
2017 Q2
Quarterly report
14 Aug 17
Current reports
8-K
Entry into a Material Definitive Agreement
26 Aug 19
8-K
Entry into a Material Definitive Agreement
19 Mar 19
8-K
LipimetiX Development Announces Sub-License of Apo E Mimetic Peptide Platform to Anji Pharma, China
7 May 18
8-K
Entry into a Material Definitive Agreement
1 Feb 18
8-K
Changes in Registrant's Certifying Accountant
14 Aug 17
8-K
Capstone Therapeutics Announces Transaction for Sale of Shares of Its Common Stock and Secured Loan
17 Jul 17
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
30 Jun 17
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
15 Jun 17
8-K
Entry into a Material Definitive Agreement
19 Apr 17
8-K
Capstone Therapeutics Announces That Its Joint Venture, LipimetiX Development, Inc., Has Closed a Series B-1 Preferred Stock Offering
26 Aug 16
Registration and prospectus
15-12G
Securities registration termination
25 Sep 19
SC 13E3/A
Going private transaction (amended)
9 Sep 19
SC 13E3/A
Going private transaction (amended)
3 Jul 19
SC 13E3
Going private transaction
31 May 19
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Mar 19
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Mar 19
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Mar 19
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Mar 19
D
$3.44M in equity / debt
17 Jul 17
8-A12G
Registration of securities
19 Apr 17
Proxies
DEF 14A
Definitive proxy
10 Jul 19
PRER14A
Preliminary revised proxy
3 Jul 19
PRE 14A
Preliminary proxy
31 May 19
DEF 14A
Definitive proxy
8 May 15
PRE 14A
Preliminary proxy
24 Apr 15
DEF 14A
Definitive proxy
2 May 14
DEF 14A
Definitive proxy
3 May 13
DEFA14A
Additional proxy soliciting materials
10 May 12
DEF 14A
Definitive proxy
10 May 12
DEFA14A
Additional proxy soliciting materials
8 Jun 11
Other
CORRESP
Correspondence with SEC
3 Jul 19
UPLOAD
Letter from SEC
28 Jun 19
UPLOAD
Letter from SEC
8 Dec 11
CORRESP
Correspondence with SEC
28 Nov 11
UPLOAD
Letter from SEC
18 Nov 11
CORRESP
Correspondence with SEC
28 Oct 11
UPLOAD
Letter from SEC
21 Oct 11
UPLOAD
Letter from SEC
17 Jun 11
CORRESP
Correspondence with SEC
16 Jun 11
UPLOAD
Letter from SEC
14 Jun 11
Ownership
SC 13D/A
Capstone Therapeutics Corp.
20 Aug 19
SC 13D/A
Capstone Therapeutics Corp.
19 Mar 19
SC 13G/A
Capstone Therapeutics Corp.
13 Feb 19
SC 13G
Capstone Therapeutics Corp.
11 Feb 19
3
Initial statement of insider ownership
4 Feb 19
4
NEIL S SUBIN
28 Dec 18
SC 13D/A
Capstone Therapeutics Corp.
20 Nov 18
SC 13D/A
Capstone Therapeutics Corp.
18 May 18
4
Matthew E. Lipman
1 Feb 18
SC 13D/A
Capstone Therapeutics Corp.
1 Feb 18